Abstract
United States In Vitro Diagnostics Investment Opportunities Analysis and
Forecasts to 2012
Summary
This report is an essential source for in-depth information and data relating
to the United States In vitro diagnostic dvices market. It also offers
detailed and comprehensive coverage of market revenue, distribution and
company share information; and latest news, financial deals and pipeline
products information of each of the key sub-segments of the In vitro
diagnostic dvices in United States.
Scope
・ The report provides in vitro diagnostics information broken down into
detailed categories and segments in United States.
・ Total revenues, end
users
・ Market shares of all the key competitors.
・ Key pipeline
products that are set to shape the market, broken down by sector.
Information on the top medical equipment companies in the sector in the
country covering business description, strategic analysis.
・ Healthcare
structure, regulatory environment, approval process, pricing trends and
reimbursement.
・ Product and brand updates, strategy changes, R&D
projects, corporate expansions and contractions and regulatory changes.
Key mergers and acquisitions, partnerships, private equity investments and
IPOs.
・ Customer, hospitals and physicians data.
Reasons to
buy
・ Gain a strong understanding of the in vitro diagnostics devices market in
United States.
・ Evaluate and compare the attractiveness of the market in
the country.
・ Identify growth segments and opportunities in each
industry sector within the country.
・ Evaluate the pipeline of key
products that will change the sector, and identify threats and opportunities
before the products are launched in the country.
・ Analyze the
competitiveness of the market in the country and identify hotspots.
Develop strategies based on the latest product, brand, expansion and research
and development news in the country.
・ Do deals with an understanding of
how competitors are financed, and the mergers and partnerships that have
shaped the market in the country.
・ Identify and analyze the strengths and
weaknesses of the industry incumbents in the country.
Table of Contents
1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 11
1.2 List of Figures 14
2 Introduction 16
2.1 What Is This Report
About? 16
3 Definitions of Markets Covered in the Report 17
3.1 In
Vitro Diagnostics Devices 17
3.2 Clinical Chemistry Test Reagents 17
3.2.1 Laboratory Reagents 17
3.2.2 Clinical Chemistry Calibrators and
Controls 17
3.2.3 Clinical Chemistry Rapid Tests 17
3.3
Immunochemistry Test Reagents 17
3.3.1 Disease Specific Markers 17
3.3.2 Disease Specific Test Reagents 18
3.3.3 Drug Related Testing
Reagents 18
3.3.4 Hormone Related Testing Reagents 19
3.3.5
Immunochemistry Calibrators and Controls 19
3.3.6 Immunochemistry Rapid
Tests 19
3.4 Blood Test Reagents 19
3.4.1 Hematology Test Reagents
20
3.4.2 Hemostasis Test Reagents 20
3.4.3 Tissue Typing Reagents
21
3.4.4 Monoclonal Antibodies 21
3.4.5 Cytokines and Immunomodulators
21
3.4.6 Histology and Cytology Reagents 21
3.5 Microbiology Test
Reagents 21
3.5.1 Bacteriology Test Reagents 21
3.5.2 Microbiology
Calibrators and Controls 22
3.5.3 Microbiology Rapid Tests 22
3.6
Infectious Immunology Test Reagents 22
3.6.1 Bacteriology 22
3.6.2
Virology 22
3.6.3 Parasitology 22
3.6.4 Infectious Immunology
Calibrators and Controls 23
3.6.5 Infectious Immunology Rapid Tests 23
3.7 Genetic Test Reagents 23
3.8 Self Testing 23
3.9 Instruments
23
4 Healthcare Sector Review 24
4.1 Healthcare Expenditure 24
4.2
Healthcare Infrastructure 29
4.2.1 Healthcare Personnel Data 30
4.2.2
Healthcare Facilities Data 33
4.3 United States Healthcare Trade
Statistics 35
5 Regulation System 36
5.1 Regulation System 36
5.2
Medical Equipment Approval Process 36
5.2.1 Pre-market Approval Process
37
5.2.2 Intended use and Indications for use 37
5.2.3 Predicate
Device 38
5.2.4 Safe and Effective 38
5.2.5 Other Category Devices
40
5.2.6 Post-Market Approval Process 41
5.2.7 Compliance and
Enforcement 41
5.2.8 Registration Fee 43
5.2.9 Approval Time 43
6
Pricing and Reimbursement 44
6.1 Government Policies 44
6.2 Private
Insurance 45
6.3 Diagnosis Related Groups (DRG) 46
7 Distribution
Structure 47
7.1 Distribution Structure 47
8 United States Medical
Equipment Cross Market Comparison 48
9 In Vitro Diagnostics In United
States 50
9.1 In Vitro Diagnostics Cross Country Comparison (2000-2012)
50
9.2 In Vitro Diagnostics, United States, Overall Revenues, 2000-2012
51
9.3 In Vitro Diagnostics, United States, Company Share (2006-2007)
57
10 Blood Test Reagents In United States 58
10.1 Blood Test Reagents
Overall Revenue (2000-2012) 58
10.1.1 Haematology Test Reagents Revenue
(2000-2012) 60
10.1.2 Hemostasis Test Reagents Revenue (2000-2012) 62
10.2 Blood Test Reagents Distribution Share (2006-2007) 64
10.3 Blood Test
Reagents, United States, Company Share (2006-2007) 65
11 Clinical
Chemistry Test Reagents In United States 66
11.1 Clinical Chemistry Test
Reagents Overall Revenue (2000-2012) 66
11.2 Clinical Chemistry Test
Reagents Distribution Share (2006-2007) 68
11.3 Clinical Chemistry Test
Reagents, United States, Company Share (2006-2007) 69
12 Genetic Test
Reagents In United States 70
12.1 Genetic Test Reagents Overall Revenue
(2000-2012) 70
12.2 Genetic Test Reagents Distribution Share (2006-2007)
72
12.3 Genetic Test Reagents, United States, Company Share (2006-2007)
73
13 Immunochemistry Test Reagents In United States 74
13.1
Immunochemistry Test Reagents Overall Revenue (2000-2012) 74
13.1.1
Disease Specific Markers Revenue (2000-2012) 77
13.1.2 Disease Specific
Test Reagents Revenue (2000-2012) 79
13.1.3 Drug Related Testing Reagents
Revenue (2000-2012) 81
13.1.4 Hormone Related Testing Reagents Revenue
(2000-2012) 83
13.2 Immunochemistry Test Reagents Distribution Share
(2006-2007) 85
13.3 Immunochemistry Test Reagents, United States, Company
Share (2006-2007) 86
14 Infectious Immunology Test Reagents In United
States 87
14.1 Infectious Immunology Test Reagents Overall Revenue
(2000-2012) 87
14.1.1 Virology Revenue (2000-2012) 90
14.2 Infectious
Immunology Test Reagents Distribution Share (2006-2007) 92
14.3 Infectious
Immunology Test Reagents, United States, Company Share (2006-2007) 93
15
Instruments In United States 94
15.1 Instruments Overall Revenue
(2000-2012) 94
15.2 Instruments Distribution Share (2006-2007) 96
15.3
Instruments, United States, Company Share (2006-2007) 97
16 Microbiology
Test Reagents In United States 98
16.1 Microbiology Test Reagents Overall
Revenue (2000-2012) 98
16.1.1 Bacteriology Test Reagents Revenue
(2000-2012) 99
16.2 Microbiology Test Reagents Distribution Share
(2006-2007) 101
16.3 Microbiology Test Reagents, United States, Company
Share (2006-2007) 102
17 Self Testing In United States 103
17.1 Self
Testing Overall Revenue (2000-2012) 103
17.2 Self Testing Distribution
Share (2006-2007) 105
17.3 Self Testing, United States, Company Share
(2006-2007) 106
18 F. Hoffmann-La Roche Ltd. Company Profile 107
18.1
Company Overview 107
18.2 Value Chain Analysis 107
18.2.1
Manufacturing 107
18.2.2 Product Development 108
18.2.3 Sales and
Marketing 109
19 Beckman Coulter, Inc. Company Profile 110
19.1
Company Overview 110
19.2 Value Chain Analysis 110
19.2.1
Manufacturing 111
19.2.2 Product Development 111
19.2.3 Sales and
Marketing 111
19.3 Beckman Coulter, Inc. Pipeline Products 112
19.3.1
Beckman Coulter, Inc. Pipeline Products by Equipment Type 112
19.3.2
Beckman Coulter, Inc. Pipeline Products by Development Stage 113
19.3.3
Beckman Coulter, Inc. Pipeline Products by Therapy Area 114
19.3.4 Beckman
Coulter, Inc. Pipeline Products by News Summary 114
20 Dade Behring
Holdings, Inc. Company Profile 115
20.1 Company Overview 115
20.2 Dade
Behring Holdings, Inc. Pipeline Products 115
20.2.1 Dade Behring Holdings,
Inc. Pipeline Products by Equipment Type 115
20.2.2 Dade Behring Holdings,
Inc. Pipeline Products by Development Stage 115
20.2.3 Dade Behring
Holdings, Inc. Pipeline Products by Therapy Area 115
20.2.4 Dade Behring
Holdings, Inc. Pipeline Products by News Summary 116
21 Abbott
Laboratories Company Profile 117
21.1 Company Overview 117
21.2 Value
Chain Analysis 117
21.2.1 Manufacturing 118
21.2.2 Product Development
118
21.2.3 Sales and Marketing 119
21.3 Abbott Laboratories Pipeline
Products 119
21.3.1 Abbott Laboratories Pipeline Products by Equipment
Type 119
21.3.2 Abbott Laboratories Pipeline Products by Development Stage
119
21.3.3 Abbott Laboratories Pipeline Products by Therapy Area 120
21.3.4 Abbott Laboratories Pipeline Products by Clinical Trials 120
21.3.5
Abbott Laboratories Pipeline Products by News Summary 120
22 Siemens
Medical Solutions Company Profile 121
22.1 Company Overview 121
22.2
Value Chain Analysis 121
22.2.1 Manufacturing 122
22.2.2 Product
Development 122
22.2.3 Sales and Marketing 122
22.3 Siemens Medical
Solutions Pipeline Products 123
22.3.1 Siemens Medical Solutions Pipeline
Products by Equipment Type 123
22.3.2 Siemens Medical Solutions Pipeline
Products by Development Stage 123
22.3.3 Siemens Medical Solutions
Pipeline Products by Therapy Area 124
22.3.4 Siemens Medical Solutions
Pipeline Products by News Summary 124
23 Gen-Probe Incorporated Company
Profile 125
23.1 Company Overview 125
23.2 Value Chain Analysis
125
23.2.1 Manufacturing 126
23.2.2 Product Development 126
23.2.3
Sales and Marketing 127
23.3 Gen-Probe Incorporated Pipeline Products
127
23.3.1 Gen-Probe Incorporated Pipeline Products by Equipment Type
127
23.3.2 Gen-Probe Incorporated Pipeline Products by Development Stage
128
23.3.3 Gen-Probe Incorporated Pipeline Products by Therapy Area
128
23.3.4 Gen-Probe Incorporated Pipeline Products by Clinical Trials
128
23.3.5 Gen-Probe Incorporated Pipeline Products by News Summary
129
24 A&G Pharmaceutical, Inc. Company Profile 130
24.1 Company
Overview 130
24.2 A&G Pharmaceutical, Inc. Pipeline Products 130
24.2.1 A&G Pharmaceutical, Inc. Pipeline Products by Equipment Type 130
24.2.2 A&G Pharmaceutical, Inc. Pipeline Products by Development Stage 130
24.2.3 A&G Pharmaceutical, Inc. Pipeline Products by Therapy Area 130
24.2.4 A&G Pharmaceutical, Inc. Pipeline Products by News Summary 131
25
Applied NeuroSolutions, Inc. Company Profile 132
25.1 Company Overview
132
26 Baxter International Inc. Company Profile 133
26.1 Company
Overview 133
26.2 Value Chain Analysis 133
26.2.1 Manufacturing
134
26.2.2 Product Development 134
26.2.3 Sales and Marketing 135
27 Biovest International, Inc. Company Profile 136
27.1 Company Overview
136
28 BioVision, Inc. Company Profile 137
28.1 Company Overview
137
29 Egenix, Inc. Company Profile 138
29.1 Company Overview 138
30 Express Biotech International Company Profile 139
30.1 Company Overview
139
31 Genomic Health, Inc. Company Profile 140
31.1 Company Overview
140
32 Genzyme Corporation Company Profile 141
32.1 Company Overview
141
33 Haemonetics Corporation Company Profile 142
33.1 Company
Overview 142
33.2 Value Chain Analysis 142
33.2.1 Manufacturing
143
33.2.2 Product Development 143
33.2.3 Sales and Marketing 144
34 ImmTech, Inc Company Profile 146
34.1 Company Overview 146
35
ImmunoVision, Inc. Company Profile 147
35.1 Company Overview 147
36
Financial Deals Landscape 148
36.1 Acquisition 148
36.1.1 Paul Kennedy
And Patrice Debregeas Acquires 72% Stakes In IVAX Diagnostics From Teva
Pharmaceutical Industries 148
36.1.2 Immucor Acquires BioArray Solutions
150
36.1.3 The Elitech To Acquire Nanogen 151
36.2 Venture Financing
153
36.2.1 Molecular Biometrics Secures $12 Million In Series A Financing
153
36.2.2 BioImagene Secures $26 Million In Series D Financing 155
36.2.3 Chronix Biomedical Secures $2.27 Million In Second Round Of Financing
156
37 Recent Developments 158
37.1 Product Annoucements 158
37.1.1 Aug 18, 2008: Biotest Receives FDA Approval To Market Its Full Line of
Traditional Blood Bank Reagents 158
38 APPENDIX 159
38.1 Global
Markets Direct Research Methodology 159
38.2 Coverage 160
38.3
Secondary Research 160
38.4 Primary Research 161
38.5 Models 161
38.6 Forecasts 162
38.7 Expert Panels 162
38.8 Currency Conversion
163
38.9 Contact Us 164
38.10 Disclaimer 164
1.1
List of Tables
Table 1: United States Healthcare Expenditure, 2003-2010
25
Table 2: United States Healthcare Expenditure by Age (per person),
2000-2003 26
Table 3: United States Healthcare Expenditure by Sex (per
person), 2000-2003 26
Table 4: United States Healthcare Expenditure by
Race (per person), 2000-2003 26
Table 5: United States Personal Healthcare
Expenditure by Type, 2000-2004 27
Table 6: United States Personal
Healthcare Expenditure by Source, 2000-2004 28
Table 7: Total Number of
Doctors in the United States, 2003-2010 30
Table 8: Number of Doctors by
Specialty in the United States, 2003-2010 31
Table 9: Doctors by Region
(Number per 10,000 Civilian Population), 2002-2004 32
Table 10: Doctors by
Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.) 33
Table
11: Total Hospitals in the United States, 2000-2004 33
Table 12: Community
Hospitals by Number of Beds in the United States, 2000-2004 34
Table 13:
Number of Hospital Beds in the United States, 2000-2004 34
Table 14:
Number of Hospital Beds by Range in the United States, 2000-2004 34
Table
15: United States Healthcare Trade Statistics, 2001-2006 35
Table 16:
Medical Equipment Registration Fee in United States, 2007 43
Table 17:
Medical Device Approval Time in United States, 2004 43
Table 18: United
States, Medical Equipment Market Comparison 49
Table 19: In Vitro
Diagnostics Cross Country Comparison (2000-2012) 50
Table 20: In
Vitro Diagnostics, United States, Overall Revenues ($ mn), 2000-2012 51
Table 21: In Vitro Diagnostics Market, United States, Portfolio Analysis
52
Table 22: In Vitro Diagnostics, United States, Overall Revenues ($
mn), Historic, 2000-2007 54
Table 23: In Vitro Diagnostics, United
States, Overall Revenues ($ mn), Forecast, 2007-2012 56
Table 24: In
Vitro Diagnostics, United States, Company Share by Revenue ($ mn), 2006-2007
57
Table 25: Blood Test Reagents, United States, Revenue ($ mn) by
Segment, Historic, 2000-2007 58
Table 26: Blood Test Reagents, United
States, Revenue ($ mn) by Segment, Forecast, 2007-2012 59
Table 27:
Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 60
Table 28: Haematology Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 61
Table 29:
Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 62
Table 30: Hemostasis Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 63
Table 31:
Blood Test Reagents, United States, Distribution Share by Revenue ($ mn),
2006-2007 64
Table 32: Blood Test Reagents, United States, Company
Share by Revenue ($ mn), 2006-2007 65
Table 33: Clinical Chemistry
Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2007
66
Table 34: Clinical Chemistry Test Reagents, United States, Revenue
($ mn) by Segment, Forecast, 2007-2012 67
Table 35: Clinical
Chemistry Test Reagents, United States, Distribution Share by Revenue ($ mn),
2006-2007 68
Table 36: Clinical Chemistry Test Reagents, United
States, Company Share by Revenue ($ mn), 2006-2007 69
Table 37:
Genetic Test Reagents, United States, Revenue ($ mn) by Segment, Historic,
2000-2007 70
Table 38: Genetic Test Reagents, United States, Revenue
($ mn) by Segment, Forecast, 2007-2012 71
Table 39: Genetic Test
Reagents, United States, Distribution Share by Revenue ($ mn), 2006-2007
72
Table 40: Genetic Test Reagents, United States, Company Share by
Revenue ($ mn), 2006-2007 73
Table 41: Immunochemistry Test Reagents,
United States, Revenue ($ mn) by Segment, Historic, 2000-2007 75
Table 42:
Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment,
Forecast, 2007-2012 76
Table 43: Disease Specific Markers, United
States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 77
Table 44:
Disease Specific Markers, United States, Revenues ($ mn) by Sub-Segment,
Forecast, 2007-2012 78
Table 45: Disease Specific Test Reagents,
United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 79
Table 46: Disease Specific Test Reagents, United States, Revenues ($ mn)
by Sub-Segment, Forecast, 2007-2012 80
Table 47: Drug Related Testing
Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
81
Table 48: Drug Related Testing Reagents, United States, Revenues
($ mn) by Sub-Segment, Forecast, 2007-2012 82
Table 49: Hormone
Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 83
Table 50: Hormone Related Testing Reagents,
United States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 84
Table 51: Immunochemistry Test Reagents, United States, Distribution
Share by Revenue ($ mn), 2006-2007 85
Table 52: Immunochemistry Test
Reagents, United States, Company Share by Revenue ($ mn), 2006-2007 86
Table 53: Infectious Immunology Test Reagents, United States, Revenue ($
mn) by Segment, Historic, 2000-2007 88
Table 54: Infectious
Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast,
2007-2012 89
Table 55: Virology, United States, Revenues ($ mn) by
Sub-Segment, Historic, 2000-2007 90
Table 56: Virology, United
States, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012 91
Table 57:
Infectious Immunology Test Reagents, United States, Distribution Share by
Revenue ($ mn), 2006-2007 92
Table 58: Infectious Immunology Test
Reagents, United States, Company Share by Revenue ($ mn), 2006-2007 93
Table 59: Instruments, United States, Revenue ($ mn) by Segment,
Historic, 2000-2007 94
Table 60: Instruments, United States, Revenue
($ mn) by Segment, Forecast, 2007-2012 95
Table 61: Instruments,
United States, Distribution Share by Revenue ($ mn), 2006-2007 96
Table
62: Instruments, United States, Company Share by Revenue ($ mn),
2006-2007 97
Table 63: Microbiology Test Reagents, United States,
Revenue ($ mn) by Segment, Historic, 2000-2007 98
Table 64:
Microbiology Test Reagents, United States, Revenue ($ mn) by Segment,
Forecast, 2007-2012 98
Table 65: Bacteriology Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 99
Table 66:
Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Forecast, 2007-2012 100
Table 67: Microbiology Test Reagents, United
States, Distribution Share by Revenue ($ mn), 2006-2007 101
Table 68:
Microbiology Test Reagents, United States, Company Share by Revenue ($ mn),
2006-2007 102
Table 69: Self Testing, United States, Revenue ($ mn)
by Segment, Historic, 2000-2007 103
Table 70: Self Testing, United
States, Revenue ($ mn) by Segment, Forecast, 2007-2012 104
Table 71:
Self Testing, United States, Distribution Share by Revenue ($ mn), 2006-2007
105
Table 72: Self Testing, United States, Company Share by Revenue
($ mn), 2006-2007 106
Table 73: Beckman Coulter, Inc. Pipeline
Products by Equipment Type 112
Table 74: Beckman Coulter, Inc.
Pipeline Products By Development Stage 113
Table 75: Beckman Coulter,
Inc. Pipeline Products By Therapy Area 114
Table 76: Beckman Coulter,
Inc. Pipeline Products By News Summaries 114
Table 77: Dade Behring
Holdings, Inc. Pipeline Products by Equipment Type 115
Table 78: Dade
Behring Holdings, Inc. Pipeline Products By Development Stage 115
Table
79: Dade Behring Holdings, Inc. Pipeline Products By Therapy Area 115
Table 80: Dade Behring Holdings, Inc. Pipeline Products By News Summaries
116
Table 81: Abbott Laboratories Pipeline Products by Equipment
Type 119
Table 82: Abbott Laboratories Pipeline Products By
Development Stage 119
Table 83: Abbott Laboratories Pipeline
Products By Therapy Area 120
Table 84: Abbott Laboratories Pipeline
Products By Clinical Trials 120
Table 85: Abbott Laboratories
Pipeline Products By News Summaries 120
Table 86: Siemens Medical
Solutions Pipeline Products by Equipment Type 123
Table 87: Siemens
Medical Solutions Pipeline Products By Development Stage 123
Table 88:
Siemens Medical Solutions Pipeline Products By Therapy Area 124
Table 89:
Siemens Medical Solutions Pipeline Products By News Summaries 124
Table 90: Gen-Probe Incorporated Pipeline Products by Equipment Type
127
Table 91: Gen-Probe Incorporated Pipeline Products By Development
Stage 128
Table 92: Gen-Probe Incorporated Pipeline Products By
Therapy Area 128
Table 93: Gen-Probe Incorporated Pipeline Products
By Clinical Trials 128
Table 94: Gen-Probe Incorporated Pipeline
Products By News Summaries 129
Table 95: A&G Pharmaceutical, Inc.
Pipeline Products by Equipment Type 130
Table 96: A&G Pharmaceutical,
Inc. Pipeline Products By Development Stage 130
Table 97: A&G
Pharmaceutical, Inc. Pipeline Products By Therapy Area 130
Table 98:
A&G Pharmaceutical, Inc. Pipeline Products By News Summaries 131
Table 99:
Currency Conversion from USD to Local Currency at 2007 Constant Rate 163
1.2 List of Figures
Figure 1: United States, Healthcare
Expenditure by Source, 2003 25
Figure 2: United States, Healthcare
Infrastructure, Top Level View, 2007 29
Figure 3: Healthcare Expenses
Segmentation by End User, 2003 30
Figure 4: Medical Equipment Approval
Process in the United States, 2007 37
Figure 5: PMA Approval Process in
the United States, 2007 39
Figure 6: The 510(k) Approval Process for
Medical Devices in the United States, 2007 40
Figure 7: Reimbursement
Structure in the United States, 2007 46
Figure 8: Distribution Structure
of Medical Equipment in the United States, 2006 47
Figure 9: United
States, Medical Equipment Market Comparison,2007 48
Figure 10: In
Vitro Diagnostics Cross Country Comparison (2000-2012) 50
Figure 11:
In Vitro Diagnostics, United States, Overall Revenues ($ mn), 2000-2012 51
Figure 12: In Vitro Diagnostics Market, United States, Portfolio Analysis
52
Figure 13: In Vitro Diagnostics, United States, Overall Revenues
($ mn), Historic, 2000-2007 53
Figure 14: In Vitro Diagnostics,
United States, Overall Revenues ($ mn), Forecast, 2007-2012 55
Figure 15:
In Vitro Diagnostics, United States, Company Share (%), 2007 57
Figure
16: Blood Test Reagents, United States, Revenue ($ mn) by Segment,
Historic, 2000-2007 58
Figure 17: Blood Test Reagents, United States,
Revenue ($ mn) by Segment, Forecast, 2007-2012 59
Figure 18:
Haematology Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 60
Figure 19: Haematology Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 61
Figure 20:
Hemostasis Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 62
Figure 21: Hemostasis Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 63
Figure 22:
Blood Test Reagents, United States, Company Share (%), 2007 65
Figure
23: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by
Segment, Historic, 2000-2007 66
Figure 24: Clinical Chemistry Test
Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012 67
Figure 25: Clinical Chemistry Test Reagents, United States, Company Share
(%), 2007 69
Figure 26: Genetic Test Reagents, United States, Revenue
($ mn) by Segment, Historic, 2000-2007 70
Figure 27: Genetic Test
Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012 71
Figure 28: Genetic Test Reagents, United States, Company Share (%), 2007
73
Figure 29: Immunochemistry Test Reagents, United States, Revenue
($ mn) by Segment, Historic, 2000-2007 74
Figure 30: Immunochemistry
Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2007-2012
76
Figure 31: Disease Specific Markers, United States, Revenues ($
mn) by Sub-Segment, Historic, 2000-2007 77
Figure 32: Disease
Specific Markers, United States, Revenues ($ mn) by Sub-Segment, Forecast,,
2007-2012 78
Figure 33: Disease Specific Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007 79
Figure 34:
Disease Specific Test Reagents, United States, Revenues ($ mn) by
Sub-Segment, Forecast,, 2007-2012 80
Figure 35: Drug Related Testing
Reagents, United States, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
81
Figure 36: Drug Related Testing Reagents, United States, Revenues
($ mn) by Sub-Segment, Forecast,, 2007-2012 82
Figure 37: Hormone
Related Testing Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 83
Figure 38: Hormone Related Testing Reagents,
United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 84
Figure 39: Immunochemistry Test Reagents, United States, Company Share
(%), 2007 86
Figure 40: Infectious Immunology Test Reagents, United
States, Revenue ($ mn) by Segment, Historic, 2000-2007 87
Figure 41:
Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment,
Forecast, 2007-2012 89
Figure 42: Virology, United States, Revenues
($ mn) by Sub-Segment, Historic, 2000-2007 90
Figure 43: Virology,
United States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 91
Figure 44: Infectious Immunology Test Reagents, United States, Company
Share (%), 2007 93
Figure 45: Instruments, United States, Revenue ($
mn) by Segment, Historic, 2000-2007 94
Figure 46: Instruments, United
States, Revenue ($ mn) by Segment, Forecast, 2007-2012 95
Figure 47:
Instruments, United States, Company Share (%), 2007 97
Figure 48:
Bacteriology Test Reagents, United States, Revenues ($ mn) by Sub-Segment,
Historic, 2000-2007 99
Figure 49: Bacteriology Test Reagents, United
States, Revenues ($ mn) by Sub-Segment, Forecast,, 2007-2012 100
Figure
50: Microbiology Test Reagents, United States, Company Share (%), 2007
102
Figure 51: Self Testing, United States, Revenue ($ mn) by
Segment, Historic, 2000-2007 103
Figure 52: Self Testing, United
States, Revenue ($ mn) by Segment, Forecast, 2007-2012 104
Figure 53:
Self Testing, United States, Company Share (%), 2007 106
Figure 54:
F. Hoffmann-La Roche Ltd Value Chain Analysis 107
Figure 55: Beckman
Coulter, Inc. Value Chain Analysis 110
Figure 56: Abbott
Laboratories Value Chain Analysis 117
Figure 57: Siemens Medical
Solutions Value Chain Analysis 121
Figure 58: Gen-Probe Incorporated
Value Chain Analysis 125
Figure 59: Baxter International Inc. Value
Chain Analysis 133
Figure 60: Haemonetics Corporation Value Chain
Analysis 142
Figure 61: Global Markets Direct Methodology 159
